Quynh Nguyen

So, what happened this year at JPM? 💊 Rakuten Medical and LOTTE Biologics have signed a contract manufacturing agreement regarding oncology. 🌏 Samsung Biologics presented a 3 pillar expansion strategy focused on manufacturing capacity, portfolio breadth, and global footprint. 🤑 NVIDIA & Eli Lilly and Company are investing $1 billion over 5 years into a joint innovation lab in South San Francisco. 🧬 Hippocratic AI is expanding into life sciences through the acquisition of agentic AI firm Grove AI and the launch of a specialized life sciences unit. 🇨🇳 AbbVie agrees to $650 million upfront to secure licensing rights to RC148, a bispecific oncology drug in clinical development from RemeGen荣昌生物. 🤖 Baxter International Inc. has introduced a new smart stretcher aimed at enhancing patient mobility and streamlining workflows for healthcare staff 🤝 Novartis struck a licensing agreement worth nearly $1.7 billion with SciNeuro Pharmaceuticals to develop antibody treatments for Alzheimers. 🖥️ VieCure, an oncology care software startup, secured $43 million in funding to scale and broaden adoption of its platform. Did I miss any big updates? Let me know in the comments. #JPM #Biotech #Pharma

34

This line from Bob Nelsen at JPM stuck with me. AI in biotech doesn’t really matter until models stop assisting and start inventing, because they’ve finally seen enough real biology. That gap, data quality, scale, wet lab feedback, clinical context, is exactly what makes this hard. It’s also why the upside is so asymmetric when it works. This is the spine of PMWC 2026 Track 2, AI & Computational Medicine. Less theory, more builders working through real biological and clinical constraints. We’ll dig into this directly with Marc Tessier-Lavigne, drawing from the work underway at Xaira Therapeutics, and others pushing toward that invention moment. Via Marc Tessier-Lavigne, quoting Bob Nelsen of ARCH Venture Partners. PMWC 2026, March 4–6 https://lnkd.in/gm9nsW_G

14

💸 $3B+ in biotech, medtech & healthtech funding this week. From RNAi licensing to AI-first primary care: here’s what happened 👇 🧬 SanegeneBio signed a global licensing deal with Genentech, receiving $200M upfront and eligibility for up to $1.5B in milestones, plus royalties, for an RNAi program based on its proprietary RNAi platform. 💊 Mirum Pharmaceuticals, Inc. completed its $810M acquisition of Bluejay Therapeutics, including $250M cash upfront, and up to $200M in sales milestones, supported by a $200M private placement financing. 🏦 Santé Ventures closed its $330M Fund V, exceeding target, to back early-stage biotech, medtech, and digital health companies addressing major unmet medical needs. 🦴 Angitia Biopharmaceuticals raised $130M Series D, co-led by Frazier Life Sciences and Venrock, with participation from RA Capital, Wellington, Ascenta Capital, and others, to advance bone disease bispecifics. 🌸 Midi Health raised $100M Series D at a $1B+ valuation, led by Goodwater Capital, with Foresite Capital, Serena Ventures, and returning investors including GV (Google Ventures) and Emerson Collective. 🤖 Alaffia Health secured $55M Series B led by Transformation Capital, with FirstMark, Tau Ventures, and Twine Ventures backing its agentic AI platform for health plan claims operations. 🧪 Biorce closed a $52.5M Series A with TZR Capital, Endeavor Catalyst, Norrsken VC and angel investors to scale its AI clinical trial platform. 🩺 Lotus Health AI raised $41M total, including a $35M Series A co-led by Kleiner Perkins and CRV, to build an AI-powered, physician-led primary care model. 🫀 Carvolix (formerly Affluent Medical) completed the acquisitions of Caranx Medical and Artedrone and secured a €10M first financing tranche from Truffle Capital and Edwards Lifesciences. 🧬 PranaX closed an oversubscribed $17M Series A, led by family offices and individual investors, to advance exosome-based regenerative biologics. ⚛️ QT Sense raised €4M, including a €3M seed led by Cottonwood Technology Fund, plus grants, to commercialize its quantum cell-analysis platform. 💬 Which breakthrough caught your eye this week? 🔔 Want this recap in your feed every week? Follow us #biotech #medtech #healthtech #fundraising #VentureCapital

8

TCG Labs Soleil has created more than 10 single-asset biotechs, which receive early-stage clinical development support from a centralized R&D team. Now, the Bay Area firm has doubled its capital pool to $800 million and opened an office in Shanghai to run even more efficiently. One of its portfolio companies, Juri Biosciences, licensed a drug from a Shanghai-based biotech earlier this year. “The science, there’s really no border,” CEO Jin-Long Chen said in an interview with Endpoints News. “It’s all about efficiency,” chief operating officer Lucinda Quan said in a joint interview. “Having boots on the ground there, keeping an ear to the innovation that’s happening there. But also we use a number of CROs globally, including in China, so having boots on the ground to manage those relationships, to cut down on the time zone differences is just all about adding to our efficiency.” #TCGLabsSoleil #thecolumngroup #biotechvc #biotechventurecapital #shanghaibiotech #chinabiotech #bayareabiotech https://lnkd.in/g45QpwpR

104

2 Comments